SolasCure has initiated a new Phase II clinical trial, CLEANVLU2, to further the development of its investigational product, ...

UK biotechnology company SolasCure has commenced the randomised, controlled CLEANVLU2 Phase II trial of Aurase Wound Gel for ...

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today ...

the CLEANVLU2 trial is set to provide crucial efficacy data to further establish the gel’s potential as the ‘first’ treatment in addressing all aspects of wound bed preparation, including debridement.

The gel is designed to be a 'safe' debrider suitable ... in addressing all aspects of wound bed preparation, including debridement. As part of the community service, the trial is being conducted ...

SolasCure, a Cambridge biotech developing a novel treatment to transform chronic wound healing, has initiated a new Phase II ...

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers SOLASCURE Ltd (SolasCure), a biotechnology company ...

Patches with a cellulose gel material can also prevent them from sliding off your face (a con I often deal with and try to avoid as much as possible). Not only is the skin under your eyes thinner ...